Kinnate Biopharma Inc. KNTE

Full chart Compare
Set alert

Price alert · KNTE

All alert types
2.65 +2.65

Day range unavailable

52-week range unavailable

Analyst view

Consensus: buy

Buy
Price target (mean) 2.36 -10.9% downside
Target (low)
2.00
Target (mean)
2.36
Target (high)
2.59
Ratings (-1m) 7 3 buy · 4 hold · 0 sell
  • Strong buy3
  • Buy0
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • 1 month ago 7
  • 2 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

KNTE analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.34-0.38 – -0.29-0.73+53.4%00.0%3
Next quarter-0.34-0.38 – -0.29-0.68+50.0%00.0%3
Current year-1.31-1.48 – -1.04-2.42+45.9%00.0%3
Next year-1.04-1.55 – -0.71-1.31+20.6%00.0%3

Upgrades and downgrades

The latest rating changes

KNTE analyst upgrades and downgrades
DateFirmActionFromTo
Sep 18, 2023JefferiesMaintainedBuyBuy
Sep 18, 2023WedbushDowngradeOutperformNeutral
Sep 18, 2023HC Wainwright & Co.DowngradeBuyNeutral
Sep 18, 2023Piper SandlerDowngradeOverweightNeutral
Aug 14, 2023HC Wainwright & Co.ReiteratedBuyBuy
Jun 7, 2023HC Wainwright & Co.ReiteratedBuyBuy
May 17, 2023HC Wainwright & Co.MaintainedBuyBuy
May 11, 2023WedbushReiteratedOutperformOutperform
May 11, 2023StifelMaintainedHoldHold
Apr 19, 2023HC Wainwright & Co.Maintained—Buy
Apr 18, 2023Goldman SachsMaintained—Buy
Apr 17, 2023Goldman SachsMaintained—Buy
Mar 19, 2023HC Wainwright & Co.Reiterated—Buy
Mar 15, 2023StifelMaintained—Hold
Mar 15, 2023WedbushMaintained—Outperform
Nov 16, 2022StifelDowngradeBuyHold
Jul 27, 2022HC Wainwright & Co.Initiated—Buy
May 23, 2022Goldman SachsMaintained—Buy
May 18, 2022Piper SandlerMaintained—Overweight
Sep 26, 2021JefferiesInitiated—Buy
Sep 22, 2021StifelInitiated—Buy
Jul 12, 2021William BlairInitiated—Outperform
Dec 27, 2020Piper SandlerInitiated—Overweight
Dec 27, 2020SVB LeerinkInitiated—Outperform